Therefore, based on our previous findings regarding the role of IFN in SLE via the JAK–STAT pathway and the fact that TOFA comprises a multi-targeted therapeutic, we evaluated the efficacy of TOFA as a novel SLE-treatment option. This evidence concerns the gene SOAT1 and systemic lupus erythematosus.